HRTX Financials: Heron Therapeutics Inc AI Analysis



Financials

HRTX Financial

Heron Therapeutics Inc

$1.19

0%

$0

As of today:Apr 28, 09:35:50 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$1.19

Open

$1.2

Day's Range

$1.18 - $1.28

52 week range

$0.7362 - $2.61

Volume

3.9M

Avg.Volume

1.8M

Dividend yield

EPS (TTM)

-0.12

Market Cap

$224.3M

What is HRTX?

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. The company is headquartered in Cary, North Carolina and currently employs 122 full-time employees. The company creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.

Features

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

HRTX Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024
Revenue	154	40	38	37	38	40
Revenue Growth (YoY)	7%	0%	19%	3%	12%	18%
Cost of Revenue	41	11	11	9	8	10
Gross Profit	113	29	26	27	30	30
Selling, General & Admin	103	25	26	26	25	23
Research & Development	12	3	3	2	2	3
Operating Expenses	116	29	30	28	27	26
Other Non Operating Income (Expenses)	1	4	-2	0	0	0
Pretax Income	-20	-2	-17	-2	2	3
Income Tax Expense	0	0	--	--	--	--
Net Income	-20	-2	-17	-2	2	3
Net Income Growth	54%	-167%	325%	-78%	-167%	-130%
Shares Outstanding (Diluted)	188.25	188.25	170.34	154.02	196.92	153.15
Shares Change (YoY)	23%	23%	11%	1%	30%	1%
EPS (Diluted)	-0.12	-0.01	-0.1	-0.01	0.01	0.02
EPS Growth	35%	-166%	224%	-74%	-164%	-134%
Free Cash Flow	-27	-9	1	-11	-8	-12
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	73.37%	72.5%	68.42%	72.97%	78.94%	75%
Operating Margin	-1.29%	0%	-10.52%	-2.7%	7.89%	10%
Profit Margin	-12.98%	-5%	-44.73%	-5.4%	5.26%	7.5%
Free Cash Flow Margin	-17.53%	-22.5%	2.63%	-29.72%	-21.05%	-30%
EBITDA	0	0	-4	-1	3	4
EBITDA Margin	0%	0%	-10.52%	-2.7%	7.89%	10%
D&A For EBITDA	2	0	0	0	0	0
EBIT	-2	0	-4	-1	3	4
EBIT Margin	-1.29%	0%	-10.52%	-2.7%	7.89%	10%
Effective Tax Rate	0%	0%	--	--	--	--

Follow-Up Questions

What are Heron Therapeutics Inc's key financial statements?



According to the latest financial statement (Form-10K), Heron Therapeutics Inc has a total asset of $0, Net loss of $0

What are the key financial ratios for HRTX?



Heron Therapeutics Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Heron Therapeutics Inc's revenue broken down by segment or geography?



Heron Therapeutics Inc largest revenue segment is Therapeutic Innovations, at a revenue of 154,904,000 in the most earnings release.For geography, United States is the primary market for Heron Therapeutics Inc, at a revenue of 154,904,000.

Is Heron Therapeutics Inc profitable?



no, according to the latest financial statements, Heron Therapeutics Inc has a net loss of $0

Does Heron Therapeutics Inc have any liabilities?



no, Heron Therapeutics Inc has liability of 0

How many outstanding shares for Heron Therapeutics Inc?



Heron Therapeutics Inc has a total outstanding shares of 0

Heron Therapeutics Inc (HRTX) Financial

HRTX Stock Price Chart